Rein Therapeutics, Inc. Common Stock
$0.80
$0.01 (+1.37%)
$0.78Day Range$0.82
Key Statistics
Market Cap
$68.08M
Shares Outstanding
86.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 29, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$0.79
Day High
$0.82
Day Low
$0.78
Volume
492.5K
VWAP
$0.80
Prev Close
$0.79
Transactions
--
Acc. Volume
--
About Rein Therapeutics, Inc. Common Stock
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
PHARMACEUTICAL PREPARATIONSSIC 283410 employees12407 N. MOPAC EXPY., AUSTIN, TX, 78758(737) 802-1989IPO Jun 29, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001420565
- Composite FIGI
- BBG002454KR1
- Share Class FIGI
- BBG002454KS0
- Ticker Root
- RNTX
- SIC Code
- 2834
About Rein Therapeutics, Inc. Common Stock (RNTX) Stock
Rein Therapeutics, Inc. Common Stock (RNTX) closed the 2026-09-18 session at $0.80, up 1.37% versus the previous close (+0.01). The stock opened at $0.79 and traded between $0.78 and $0.82 during that session. Session trading volume was 492K shares. The volume-weighted average price (VWAP) is $0.80.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Rein Therapeutics, Inc. Common Stock has a market capitalization of $68.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RNTX is listed on the XNAS exchange. The company employs approximately 10 people. Rein Therapeutics, Inc. Common Stock is headquartered in AUSTIN, TX. The recorded listing date is 2017-06-29.
On this page you can find market RNTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.